Zydus Lifesciences Depression drug Doxepin Hydrochloride bags USFDA okay

The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, India.

Published On 2023-03-24 05:54 GMT   |   Update On 2023-03-24 05:54 GMT
Advertisement

Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval for Doxepin Hydrochloride Capsules USP, 150 mg (USRLD: Sinequan Capsules) from the United States Food and Drug Administration (USFDA).

Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level.

The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, India).

Doxepin Hydrochloride Capsules USP, 150 mg had annual sales of USD 2.11 mn in the United States (IQVIA MAT Jan. 2023). The group now has 353 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Medical Dialogues team had earlier reported that Zydus Lifesciences had received final approval from the USFDA to manufacture and market Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg (USRLD: Zyprexa Zydis Orally Disintegrating Tablets).

Read also: Zydus bags USFDA nod for Olanzapine Orally Disintegrating Tablets to treat certain mental conditions

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Read also: USFDA grants Orphan Drug Designation to Zydus's ZYIL1 for treatment of Cryopyrin Associated Periodic Syndrome

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News